Breast cancer online : BCO最新文献

{"title":"Basic science: (December 2007)","authors":"R. Sutherland","doi":"10.1017/S1470903108008316","DOIUrl":"https://doi.org/10.1017/S1470903108008316","url":null,"abstract":"cancer risk BRCA2 mutation carriers: results from a combined analysis of 19 studies.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108008316","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status of adjuvant bisphosphonates in operable breast cancer","authors":"A. Paterson","doi":"10.1017/S1470903108004343","DOIUrl":"https://doi.org/10.1017/S1470903108004343","url":null,"abstract":"Bisphosphonates offer a potentially effective adjuvant therapy to reduce recurrence of bone metastases in breast cancer patients. Clinical trials are at the early stage, but initial results have shown promise. There are three published adjuvant trials of oral clodronate, and one trial each of pamidronate and zoledronic acid. Observed complications so far include osteonecrosis of the jaw or maxilla because bisphosphonates inhibit bone turnover, as well as renal toxicity. Thus, care needs to be taken with dosage and duration of treatment and patients carefully managed.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108004343","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic mammotome excisions: radial scars","authors":"J. Morel, M. Michell","doi":"10.1017/S1470903108004975","DOIUrl":"https://doi.org/10.1017/S1470903108004975","url":null,"abstract":"Benign radial scars, lesions characterised histologically by a fibroelastic core surrounded by stellate duct proliferation, cannot be differentiated from lesions with associated invasive or non-invasive carcinoma on imaging, and histological sampling is therefore mandatory. There is also extensive evidence of the frequency with which radial scars are associated with malignancy and with other lesions that have an associated risk of malignancy. The traditionally accepted management has been the surgical excision of all suspected radial scars because insufficient tissue was removed by standard biopsy techniques to exclude associated lesions. In more recent series, it has been shown that with extensive tissue sampling of such lesions with core biopsy and modern vacuum-assisted sampling devices, the presence of associated malignancy can be excluded, thus negating the need for surgical excision.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108004975","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of: Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells","authors":"A. Butt","doi":"10.1017/S1470903108006676","DOIUrl":"https://doi.org/10.1017/S1470903108006676","url":null,"abstract":"of the original article: Tamoxifen (TAM), is widely used as a single agent in adjuvant treatment of breast cancer. Here, we invest-igated the effects of TAM in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in estrogen receptor- a (ER- a )-positive and -negative breast cancer cells. We showed that cotreatment with TAM and TRAIL synergistically induced apoptosis regardless of ER- a status. By contrast, cotreatment did not affect the viability of normal breast epithelial cells. Cotreatment with TAM and TRAIL in breast cancer cells decreased the levels of antiapoptotic proteins including FLIPs and Bcl-2, and enhanced the levels of proapoptotic proteins such as FADD, caspase 8, tBid, Bax and caspase 9. Furthermore, cotreatment-induced apoptosis was efficiently reduced by FADD- or Bid-siRNA, indicating the implication of both extrinsic and intrinsic pathways in synergistic apoptosis induction. Importantly, cotreatment totally arrested tumor growth in an ER- a -negative MDA-MB-231 tumor xenograft model. The abrogation of tumor growth correlated with enhanced apoptosis in tumor tissues.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108006676","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indications for the sentinel node: multicentric, size of tumor, prior surgery","authors":"L. Hanker, A. Rody, E. Ruckhaeberle, M. Kaufmann","doi":"10.1017/S1470903107006116","DOIUrl":"https://doi.org/10.1017/S1470903107006116","url":null,"abstract":"Sentinel lymph node biopsy (SLNB) has been adopted as an applicable alternative to the standard axillary lymph node dissection (ALND) level I and II. It makes possible a less extensive axillary surgery in patients with early breast cancer with negative lymph node, who would not benefit from further dissection, in order to prevent unnecessary morbidity. On the other hand, SLNB is not appropriate in every clinical circumstance. In some clinical situations like tumor size T1 and T2, SLNB is, meanwhile, regarded as a standard procedure. In other settings like increased age and body mass index, pregnancy, ductal carcinoma in situ (DCIS), neoadjuvant chemotherapy, advanced disease (T3 and T4), prior surgery and multifocal/ multicentric disease, there is a controversial debate about the importance of SLNB. This article reviews the absolute and relative contraindications of this procedure in respect to the latter three clinical situations. For the advanced breast cancers T3 and T4, there seems to be an increasing evidence of an acceptable accuracy, although it should be further evaluated in randomized clinical trials (RCT). The indication of SLNB in previously operated patients depends on the type of prior surgery. A diagnostic biopsy does not represent a contraindication, whereas the sentinel node biopsy should not be used after an extensive breast surgery neither in the context of oncologic nor non-oncologic purposes. In the context of multicentric disease, there is growing evidence that SLNB is suitable, but actually it should be restricted to RCT. However, the multifocal disease is only a relative contraindication, that is it could be applied in well-selected patients.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903107006116","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic science: (OCTOBER 2007)","authors":"R. Sutherland","doi":"10.1017/S1470903107006657","DOIUrl":"https://doi.org/10.1017/S1470903107006657","url":null,"abstract":"1. Cao YX, Luo JL and Karin M. IkB kinase a kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumorinitiating cells. Proc Natl Acad Sci USA 2007; 104: 15852–15857. 2. Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, Cervera N, Geneix J, Hassanein M, Rabayrol L, Sobol H, Taranger-Charpin C, Xerri L, Viens P, Birnbaum D and Jacquemier J. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007; 121: 1779–1785. 3. Cheng JW, Yu DV, Zhou JH and Shapiro DJ. Tamoxifen induction of CCAAT enhancerbinding protein a is required for tamoxifeninduced apoptosis. J Biol Chem 2007; 282: 30535–30543. 4. Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, Orend G and Chiquet-Ehrismann R. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Res 2007; 67: 9169–9179. 5. Durocher F, Labrie Y, Ouellette G and Simard J. Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. J Hum Genet 2007; 52: 963–977. 6. Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BBL and Shackney SE. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007; 6: 2664–2674. 7. Jakobsen CG, Rasmussen N, Laenkholm AV and Ditzel HJ. Phage display-derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res 2007; 67: 9507–9517. 8. John EM, Schwartz GG, Koo J, Wang W and Ingles SA. Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Breast Cancer Risk in a Multiethnic Population. Am J Epidemiol 2007; 166: 1409–1419. 9. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557–563. 10. Khaleque MA, Bharti A, Gong J, Gray PJ, Sachdev V, Ciocca DR, Stati A, Fanelli M and Calderwood SK. Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene 2007; 10.1038/sj.onc.1210834. 11. Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y, Tanaka S, Yoshida T, Ishihara H and Noguchi S. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 2007; 10.1093/ annonc/mdm358. 12. Kotzsch M, Sieuwerts A, Grosser M, Meye A, Fuessel S, Meijer-van Gelder M, Smid M, Schmitt M, Baretton G, Luther T, Magdolen V and Foekens J. Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res Treat 2007; 10.1007/s10549-0079782-6. 13. Lauber SN and Gooderharn NJ. The cooked meat-derived genot","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903107006657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer","authors":"A. Swarbrick","doi":"10.1017/S1470903108006688","DOIUrl":"https://doi.org/10.1017/S1470903108006688","url":null,"abstract":"Citation of the original article: L. Ma, J. Teruya-Feldstein, R. A. Weinberg. Nature 2007; 449 (7163): 682–688; Epub 26 September 2007. Abstract of the original article: MicroRNAs have been implicated in regulating diverse cellular pathways. Although there is emerging evidence that some microRNAs can function as oncogenes or tumour suppressors, the role of microRNAs in mediating cancer metastasis remains unexplored. Here we show, using a combination of mouse and human cells, that microRNA-10b (miR-10b) is highly expressed in metastatic breast cancer cells and positively regulates cell migration and invasion. Overexpression of miR-10b in otherwise non-metastatic breast tumours initiates robust invasion and metastasis. Expression of miR-10b is induced by the transcription factor Twist, which binds directly to the putative promoter of miR-10b (MIRN10B). The miR-10b induced by Twist proceeds to inhibit translation of the messenger RNA encoding homeobox D10, resulting in increased expression of a well-characterized pro-metastatic gene, RhoC. Significantly, the level of miR-10b expression in primary breast carcinomas correlates with clinical progression. These findings suggest the workings of an undescribed regulatory pathway, in which a pleiotropic transcription factor induces expression of a specific microRNA, which suppresses its direct target and in turn activates another pro-metastatic gene, leading to tumour cell invasion and metastasis.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903108006688","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic science: (SEPTEMBER 2007)","authors":"R. Sutherland","doi":"10.1017/S1470903107006347","DOIUrl":"https://doi.org/10.1017/S1470903107006347","url":null,"abstract":"1. Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A and Aldaz CM. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 2007; 5: 881–890. 2. Alarmo EL, Korhonen T, Kuukasjaervi T, Huhtala H, Holli K and Kallioniemi A. Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas. Ann Oncol 2007; 10.1093/annonc/mdm453. 3. Andarawewa KL, Erickson AC, Chou WS, Costes SV, Gascard P, Mott JD, Bissell MJ and Barcellos-Hoff MH. Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor b-induced epithelial to mesenchymal transition. Cancer Res 2007; 67: 8662–8670. 4. Balasubramanian SP, Cox A, Cross SS, Higham SE, Brown NJ and Reed MW. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer 2007; 121: 1009–1016. 5. Bromberg KD, Kluger HM, Delaunay A, Abbas S, DiVito KA, Krajewski S and Ronai Z. Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer. Cancer Res 2007; 67: 8172–8179. 6. Buijs JT, Henriquez NV, Van Overveld PGM, Van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clezardin P, Papapoulos SE, Cecchini MG, Lowik C and Van der Pluijm G. Bone morphogenetic protein 7 in the development and treatment of bone Metastases from breast cancer. Cancer Res 2007; 67: 8742–8751. 7. Cao Y, Luo J and Karin M. IkB kinase a kinase activity is required for self-renewal of ErbB2/ Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA 2007; 104: 15852–15857. 8. Chen D, Reierstad S, Lin Z, Lu M, Brooks C, Li N, Innes J and Bulun SE. Prostaglandin E-2 induces breast cancer-related aromatase promoters via activation of p38 and c-jun NH2Terminal kinase in adipose fibroblasts. Cancer Res 2007; 67: 8914–8922. 9. Christov K, Grubbs CJ, Shilkaitis A, Juliana MM and Lubet RA. Short-term modulation of cell proliferation and apoptosis and preventive/ Therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007; 13: 5488–5496. 10. Dairkee SH, Nicolau M, Sayeed A, Champion S, Ji Y, Moore DH, Yong B, Meng Z and Jeffrey SS. Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. Oncogene 2007; 26: 6269–6279. 11. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee E, Medina D, Shih JH and Green JE. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007; 67: 8065–8080. 12. Dupont VN, Gentien D, Oberkampf M, De Rycke Y and Blin N. A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 2007; 121: ","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2007-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903107006347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of: Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women","authors":"G. Severi","doi":"10.1017/S1470903107006554","DOIUrl":"https://doi.org/10.1017/S1470903107006554","url":null,"abstract":"Citation of original article: C. A. Haiman, L. Dossus, V. W. Setiawan, D. O. Stram, A. M. Dunning, G. Thomas, M. J. Thun, D. Albanes, D. Altshuler, E. Ardanaz, H. Boeing, J. Buring, N. Burtt, E. E. Calle, S. Chanock, F. Clavel-Chapelon, G. A. Colditz, D. G. Cox, H. S. Feigelson, S. E. Hankinson, R. B. Hayes, B. E. Henderson, J. N. Hirschhorn, R. Hoover, D. J. Hunter, R. Kaaks, L. N. Kolonel, L. Le Marchand, P. Lenner, E. Lund, S. Panico, P. H. Peeters, M. C. Pike, E. Riboli, A. Tjonneland, R. Travis, D. Trichopoulos, S. Wacholder, R. G. Ziegler. Cancer Research 2007; 67 (5): 1893–1897. Abstract of the original article: The CYP19A1 gene encodes the enzyme aromatase, which is responsible for the final step in the biosynthesis of estrogens. In this study, we used a systematic two-step approach that included gene resequencing and a haplotype-based analysis to comprehensively survey common genetic variation across the CYP19A1 locus in relation to circulating postmenopausal steroid hormone levels and breast cancer risk. This study was conducted among 5,356 invasive breast cancer cases and 7,129 controls comprised primarily of White women of European descent drawn from five large prospective cohorts within the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. A high-density single-nucleotide polymorphism (SNP) map of 103 common SNPs (⩾5% frequency) was used to identify the linkage disequilibrium and haplotype patterns across the CYP19A1 locus, and 19 haplotype-tagging SNPs were selected to provide high predictability of the common haplotype patterns. We found haplotype-tagging SNPs and common haplotypes spanning the coding and proximal 5′ region of CYP19A1 to be significantly associated with a 10% to 20% increase in endogenous estrogen levels in postmenopausal women [effect per copy of the two-SNP haplotype rs749292-rs727479 (A-A) versus noncarriers; P = 4.4 × 10(−15)]. No significant associations were observed, however, with these SNPs or common haplotypes and breast cancer risk. Thus, although genetic variation in CYP19A1 produces measurable differences in estrogen levels among postmenopausal women, the magnitude of the change was insufficient to contribute detectably to breast cancer.","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2007-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903107006554","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basic science: (AUGUST 2007)","authors":"R. Sutherland","doi":"10.1017/S1470903107006633","DOIUrl":"https://doi.org/10.1017/S1470903107006633","url":null,"abstract":"1. Akli S, Van Pelt CS, Bui TY, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARFp53 pathway. Cancer Res 2007; 67: 7212–7222. 2. Almquist M, Manjer J, Bondeson L, Bondeson AG. Serum calcium, breast cancer risk: results from a prospective cohort study of 7,847 women. Cancer Causes Control 2007; 18: 595–602. 3. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. FOXA1 expression in breast cancer – correlation with luminal subtype A and survival. Clin Cancer Res 2007; 13: 4415–4421. 4. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Mader RM, Gnant M, Jakesz R, Rudas M, Zielinski CC, Steger GG. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res 2007; 13: 4435–4439. 5. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL. Serial transplantation of NMUinduced rat mammary tumors: a model of human breast cancer progression. Int J Cancer 2007; 121: 474–485. 6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429–4434. 7. Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG, Gonda TJ. Mechanism of and requirement for estrogenregulated MYB expression in estrogenreceptor-positive breast cancer cells. Proc Natl Acad Sci USA 2007; 104: 13762–13767. 8. Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J. Protein kinase C a is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat 2007; 104: 165–179. 9. Gadir N, Jackson DN, Lee E, Foster DA. Defective TGF-b signaling sensitizes human cancer cells to rapamycin. Oncogene 2007; 10.1038/sj.onc.1210721. 10. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, Worrall L, Gillies RJ. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer 2007; 97: 646–653. 11. Glass AG, Lacey JV, Carreon D, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152–1161. 12. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007; 12: 160–170. 13. Klein A, Wessel R, Graessmann M, Juergens M, Petersen I, Schmutzler R, Niederacher D, Arnold N, Meindl A, Scherneck S, Seitz S, Graessmann A. Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. Int J Cancer 2007; 121: 683–688. 14. Kotamraju S, Willams CL, Kalyanaraman B. Statin-induced brea","PeriodicalId":89901,"journal":{"name":"Breast cancer online : BCO","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2007-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/S1470903107006633","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56921039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}